Cyasterone

| Cat. No.: | HY-N0211 |
|--------------------|---|
| CAS No.: | 17086-76-9 |
| Molecular Formula: | C ₂₉ H ₄₄ O ₈ |
| Molecular Weight: | 520.65 |
| Target: | EGFR; Apoptosis |
| Pathway: | JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Apoptosis |
| Storage: | 4°C, protect from light |
| | * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |

Product Data Sheet

SOLVENT & SOLUBILITY

| In Vitro DMS | DMSO : 100 mg/mL (192.07 mM; Need ultrasonic) | | | | | | |
|--------------|--|-------------------------------|-----------|-----------|------------|--|--|
| | Preparing Stock Solutions | Solvent Mass Concentration | 1 mg | 5 mg | 10 mg | | |
| | | 1 mM | 1.9207 mL | 9.6034 mL | 19.2068 mL | | |
| | | 5 mM | 0.3841 mL | 1.9207 mL | 3.8414 mL | | |
| | | 10 mM | 0.1921 mL | 0.9603 mL | 1.9207 mL | | |
| | Please refer to the solubility information to select the appropriate solvent. | | | | | | |
| In Vivo | Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (4.80 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil | | | | | | |
| | Solubility: ≥ 2.5 mg/mL (4.80 mM); Clear solution | | | | | | |

| BIOLOGICALACTIVITY | | | | |
|---------------------------|--|--|--|--|
| Description | Cyasterone, a natural EGFR inhibitor, mainly isolated from Ajuga decumbens Thunb (Labiatae). Cyasterone manifests anti- proliferation effect by induced apoptosis and cell cycle arrests. Cyasterone may serves as a therapeutic anti-tumor agent against human tumors ^[1] . | | | |
| IC ₅₀ & Target | IC50: EGFR ^[1] | | | |
| In Vitro | Cyasterone exerts cytotoxicity on multiple cell lines: HeLa (IC ₅₀ =77.24 μg/ml); HepG-2 (IC ₅₀ =52.03 μg/ml); MCF-7 (IC ₅₀ =82.07 μg/ml) and MCF-7 (IC ₅₀ =82.07 μg/ml). And It has none cytotoxicity (IC ₅₀ >400 μg/ml) on 3 types of carcinoma (HT-29, Caco-2, T47D) and 1 type of normal (NIH 3T3) cell lines ^[1] . Cyasterone (0-60 μg/ml; 48 hours) causes a significantly decreasing of the cell proliferation. It inhibits cell growth as a dose-dependent manner, exhibits IC ₅₀ values of 38.50 μg/ml and 32.96 μg/ml, respectively ^[1] . | | | |
| | | | | |



| | Cyasterone (0-60 μg/ml; 24 hours) decreases p-EGFR, p-MEK, and p-mTOR as a dose-dependent manner in A549 cells, i affects the MAPK signaling pathway activities ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay ^[1] | | | | | |
|---------|---|--|--|--|--|--|
| | Cell Line: | A549 cells and MGC823 cells | | | | |
| | Concentration: | 0 μg/ml, 20 μg/ml, 40 μg/ml, 60 μg/ml | | | | |
| | Incubation Time: | 24 hours | | | | |
| | Result: | Inhibited cell proliferation as a dose-dependent manner. | | | | |
| | Western Blot Analysis ^[1] | Western Blot Analysis ^[1] | | | | |
| | Cell Line: | A549 cells | | | | |
| | Concentration: | 0 μg/ml, 20 μg/ml, 40 μg/ml, 60 μg/ml | | | | |
| | Incubation Time: | 24 hours | | | | |
| | Result: | Surpressed p-EGFR, p-MEK, and p-mTOR expression. | | | | |
| In Vivo | Cyasterone (intraperitoneal injection; 5 mg/kg, 10 mg/kg and 15 mg/kg; 21 days) has anti-proliferation effect in vivo and inhibits MGC823 cells xenografted tumor growth in vivo with few changes in body weights ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. | | | | | |
| | Animal Model: | MGC823 xenograft tumor in BALB/C-nu mice ^[1] | | | | |
| | Dosage: | 5 mg/kg, 10 mg/kg and 15 mg/kg | | | | |
| | Administration: | Intraperitoneal injection | | | | |
| | Result: | Inhibited MGC823 xenograft tumor growth in vivo. | | | | |

REFERENCES

[1]. Lu X, et al. Anti-proliferation effects, efficacy of cyasterone in vitro and in vivo and its mechanism. Biomed Pharmacother. 2016 Dec;84:330-339.

[2]. Lu X, et al. Anti-proliferation effects, efficacy of cyasterone in vitro and in vivo and its mechanism. Biomed Pharmacother. 2016 Dec;84:330-339.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA